CN115444893B - Uric acid reducing active substance composition and application thereof - Google Patents
Uric acid reducing active substance composition and application thereof Download PDFInfo
- Publication number
- CN115444893B CN115444893B CN202211071108.0A CN202211071108A CN115444893B CN 115444893 B CN115444893 B CN 115444893B CN 202211071108 A CN202211071108 A CN 202211071108A CN 115444893 B CN115444893 B CN 115444893B
- Authority
- CN
- China
- Prior art keywords
- leaf extract
- uric acid
- ampelopsis grossedentata
- composition
- lotus leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 59
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 229940116269 uric acid Drugs 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 239000013543 active substance Substances 0.000 title claims abstract description 11
- 230000001603 reducing effect Effects 0.000 title description 20
- 239000000284 extract Substances 0.000 claims abstract description 103
- 241001018563 Nekemias grossedentata Species 0.000 claims abstract description 70
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 59
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 59
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 59
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 12
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 23
- 108010093894 Xanthine oxidase Proteins 0.000 description 21
- 102100033220 Xanthine oxidase Human genes 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 16
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 7
- 229940075420 xanthine Drugs 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 201000005569 Gout Diseases 0.000 description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 5
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 5
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229960003459 allopurinol Drugs 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960002708 antigout preparations Drugs 0.000 description 2
- BZKUYNBAFQJRDM-UHFFFAOYSA-N aporphine Chemical group C12=CC=CC=C2CC2N(C)CCC3=CC=CC1=C32 BZKUYNBAFQJRDM-UHFFFAOYSA-N 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 244000036905 Benincasa cerifera Species 0.000 description 1
- 235000011274 Benincasa cerifera Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000219099 Parthenocissus quinquefolia Species 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 description 1
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- QCMQEZNBBPGFKQ-UHFFFAOYSA-N Thalisopynine Natural products CN1CCC2=C(OC)C(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 QCMQEZNBBPGFKQ-UHFFFAOYSA-N 0.000 description 1
- 241000046198 Triteleia hyacinthina Species 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001387 apium graveolens Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940089639 cornsilk Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000020931 dietary conditions Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000001231 zea mays silk Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a uric acid-reducing active substance composition and application thereof, wherein the composition takes ampelopsis grossedentata leaf extract and lotus leaf extract as active ingredients, and experimental results show that the composition obviously reduces serum uric acid level of hyperuricemia models caused by potassium oxazinate, can be applied to developing uric acid-reducing medicines, and has simple preparation process and high safety.
Description
Technical Field
The invention belongs to the field of pharmacy, and relates to a product with auxiliary uric acid reducing function developed by using ampelopsis grossedentata leaf extract.
Background
The end product of purine metabolism is uric acid, most uric acid generated by purine metabolism in a normal state is discharged out of the body through kidneys and biliary tracts, and if the purine metabolism system is disturbed in the body, the uric acid level of the end product is increased, so that hyperuricemia is caused. The internationally diagnostic of hyperuricemia is defined as: under normal purine dietary conditions, men have fasting blood uric acid levels of >420 μmol/L for 2 times a day and women have >360 μmol/L. With the improvement of living standard, various high-protein diets enter a dining table, the ingestion of purine in protein foods is greatly increased by modern people, and the prevalence of hyperuricemia has a gradually rising trend in recent years, and the prevalence age of hyperuricemia has a gradually younger trend.
Hyperuricemia is the causative agent of the disease and the manifestation of the initial stage, when the concentration of uric acid is too high and/or in an acidic environment, uric acid can precipitate out crystals, deposit on the tissues such as bone joints, kidneys and subcutaneous skin, cause histopathological changes, cause gouty arthritis, gout kidneys, tophus and the like. Gout causes physiological burden to individuals, and serious gout symptoms influence normal work, so that immeasurable economic loss is caused. Thus, the control of gout sources and their symptoms is urgent.
Allopurinol, probenecid, colchicine, non-steroidal anti-inflammatory drugs, glucocorticoids and the like are currently commonly used anti-gout drugs, and dominate the anti-gout drug market. However, these medicines have serious adverse reactions, especially have great toxic and side effects on kidneys and related organs, are difficult to take for a long time, and are limited in clinical application. Therefore, the development of novel low-toxicity uric acid-reducing active substances with low side effects from food sources has important significance.
Ampelopsis grossedentata is a perennial woody vine of Vitaceae, ampelopsis. The application of the ampelopsis grossedentata leaves is carried in the tea menstruation, and most of the ampelopsis grossedentata leaves are mainly used for preparing crude tea beverage products although the ampelopsis grossedentata resources are rich, and the development availability is not high. The ampelopsis grossedentata leaf contains various chemical components such as flavonoid, phenols, steroids, polysaccharides, volatile oil and the like, and the research shows that the ampelopsis grossedentata leaf and the extract thereof have various pharmacological activities such as anti-inflammatory, antibacterial, liver function protecting, blood glucose and lipid reducing, antithrombotic, antitumor, atherosclerosis resisting, cardiovascular protection and the like. The dihydromyricetin is the main flavonoid component in Ampelopsis grossedentata leaf, and is one of the main components in Ampelopsis grossedentata leaf for exerting pharmacological action. Researches show that dihydromyricetin in ampelopsis grossedentata leaves has good effect of treating hyperuricemia, and can also correct the disordered renal function and improve the pathological changes of the kidney.
The lotus leaf is a Chinese medicine with homology of medicine and food, has biological activities of reducing blood fat, resisting oxidation and the like, has no obvious toxic or side effect and has higher safety. The lotus leaf mainly contains chemical components such as alkaloids, flavonoid, volatile oil and the like, and the nuciferine is aporphine type alkaloid which is a main medicinal component in the lotus leaf, can stimulate insulin secretion, prevent and treat atherosclerosis and nonalcoholic fatty liver, and has obvious pharmacological activity in the aspects of relieving hyperuricemia kidney inflammation and protecting kidney. The lotus leaf lipid-lowering soup and the ginseng-lotus lipid-liver soup which clinically take lotus leaves as main medicines have the effect of lowering serum uric acid level, but the lotus leaf lipid-lowering soup and the ginseng-lotus lipid-liver soup are not suitable for long-term administration due to numerous medicinal ingredients and insufficient safety.
The uric acid reducing composition disclosed in chinese patent CN114224957a comprises vine tea extract and cordyceps militaris extract. Although this patent suggests that ampelopsis grossedentata extract contains dihydromyricetin, an uric acid-lowering active substance, and that ampelopsis grossedentata extract has a certain xanthine oxidase inhibitory effect in vitro, it also provides experimental results that ampelopsis grossedentata extract cannot lower the blood uric acid level of hyperuricemia patients, and that the reduction of blood uric acid of hyperuricemia patients after administration of the composition is only about 17% at maximum.
Chinese patent CN109170059a discloses a teabag made from lotus leaf, blueberry leaf, licorice and auxiliary materials. Although the patent suggests that blueberry leaves in the tea bag formula can enhance the inhibition effect of lotus leaves on xanthine oxidase, the conclusion about reducing uric acid level of human bodies is only a conjecture which is made in the absence of reliable experimental evidence under the condition of only carrying out efficacy experiments on the inhibition rate of xanthine oxidase in vitro by tea soup and lacking pharmacological experiment verification, so that the conjecture is difficult to be referred to.
Disclosure of Invention
The invention aims to provide an active substance composition for reducing uric acid and application thereof, and solves the problem of insufficient efficacy of ampelopsis grossedentata leaf extract in developing auxiliary uric acid reducing medicines.
In order to achieve the above purpose, the invention adopts the following technical scheme:
an uric acid reducing active substance composition comprises 5-15 parts by weight of Ampelopsis grossedentata leaf extract and 1-14 parts by weight of lotus leaf extract.
Preferably, in the composition, the lotus leaf extract is 1-8 parts.
Preferably, the ampelopsis grossedentata leaf extract is prepared by extracting ampelopsis grossedentata leaves with water, concentrating and drying, and the specific preparation method comprises the following steps: extracting dried Ampelopsis grossedentata leaf with 10-20 times of water for 2-4 times each for 1-3 hr (extraction temperature is 70-100deg.C), mixing the extractive solutions, concentrating under normal pressure (temperature is 70-100deg.C), and drying (temperature is 40-80deg.C for 24-48 hr).
Preferably, the content of dihydromyricetin in the ampelopsis grossedentata leaf extract is 20% -40%.
Preferably, the lotus leaf extract is prepared by extracting lotus leaves with water, concentrating and drying, and the specific preparation method comprises the following steps: extracting dried folium Nelumbinis with 20-40 times of water for 2-4 times each for 1-2 hr (extraction temperature 70-100deg.C), mixing the extractive solutions, concentrating under normal pressure (temperature 70-100deg.C), and drying (temperature 40-80deg.C for 24-48 hr).
Preferably, the nuciferine content of the lotus leaf extract is 1% -10%.
Preferably, the mass ratio of the ampelopsis grossedentata leaf extract to the lotus leaf extract in the composition is (1-4): 1-2.
Preferably, the mass ratio of the ampelopsis grossedentata leaf extract to the lotus leaf extract in the composition is 2-4:1.
Preferably, in the composition, the mass fraction of the ampelopsis grossedentata leaf extract is more than or equal to 40%, and the mass fraction of the lotus leaf extract is less than or equal to 60%.
Preferably, the composition comprises 40% -94% of ampelopsis grossedentata leaf extract and 6% -60% of lotus leaf extract by mass fraction.
Preferably, the composition comprises 65% -85% of ampelopsis grossedentata leaf extract and 15% -35% of lotus leaf extract by mass fraction.
Preferably, the composition consists of 80% of ampelopsis grossedentata leaf extract and 20% of lotus leaf extract by mass fraction.
The application of the uric acid reducing active substance composition in preparing medicines for treating hyperuricemia.
Preferably, the ampelopsis grossedentata leaf extract is a competitive inhibitor of xanthine oxidase.
Preferably, the lotus leaf extract cooperates with the ampelopsis grossedentata leaf extract to inhibit the activity of xanthine oxidase and enhance the uric acid reducing effect of the ampelopsis grossedentata leaf extract.
The beneficial effects of the invention are as follows:
according to the auxiliary treatment effect of dihydromyricetin in ampelopsis grossedentata leaves in resisting hyperuricemia, the active substance composition formed by compatibility of ampelopsis grossedentata leaf extract (such as water extract) and lotus leaf extract (such as water extract) has obvious uric acid reducing effect, and through the verification of a hyperuricemia model, the composition can reduce blood uric acid by more than 40%. Meanwhile, the composition has the advantages of simple active ingredient formulation and less auxiliary ingredients when being used for preparation, and can provide safe and effective hyperuricemia resisting effect.
Furthermore, the uric acid reducing active substance composition has stronger inhibition effect on xanthine oxidase activity by introducing the lotus leaf extract with a certain proportion, can obviously improve the symptom of abnormal rise of serum uric acid level existing in hyperuricemia, and achieves better uric acid reducing effect.
Detailed Description
The present invention is described in further detail below with reference to examples, which are only for the purpose of illustrating the present invention, but are not to be construed as limiting the scope of the present invention.
The invention determines that ampelopsis grossedentata leaves and lotus leaves have stronger synergistic inhibition effect on xanthine oxidase in vitro by primarily screening 22 medicinal and edible raw materials with uric acid reducing function, wherein the 22 medicinal and edible raw materials specifically comprise: corn silk, pagodatree flower bud, peony flower, chrysanthemum, lotus leaf, honeysuckle, chinese yam, reed rhizome, dried houttuynia cordata, gardenia, dandelion, papaya, cassia seed, white hyacinth bean, coix seed, poria cocos, white gourd peel, broccoli seed, celery seed, nude algae, inulin and ampelopsis grossedentata leaf. The efficacy of a combination of ampelopsis grossedentata leaf extract and lotus leaf extract in anti-hyperuricemia is examined as follows.
Preparation of Ampelopsis grossedentata leaf extract and lotus leaf extract
1.1 preparation Process of Ampelopsis grossedentata leaf extract
Soaking dried Ampelopsis grossedentata leaf 10kg with 20 times (L) purified water for 20min, heating (100deg.C) for 2 times, each for 1 hr, filtering, mixing filtrates, concentrating the extractive solution (at normal pressure and 100deg.C), and drying at 80deg.C for 36 hr to obtain Ampelopsis grossedentata leaf extract 2.5kg.
1.2 identification of the Components of Ampelopsis grossedentata leaf extract
Taking a ampelopsis grossedentata leaf extract sample, and detecting the dihydromyricetin content in the ampelopsis grossedentata leaf extract sample: liquid chromatography (column temperature 30 ℃ C., detection wavelength 289 nm) is adopted, dihydromyricetin is used as a reference substance, a mobile phase is added for dilution, a sample solution of 0.05mg/mL is prepared, methanol-0.05% phosphoric acid solution (methanol: 0.05% phosphoric acid solution volume ratio=35:65) is used as a mobile phase for elution, and the content of the dihydromyricetin in a sample is finally measured to be 24.31% through linear relation investigation and peak area measurement.
1.3 preparation Process of lotus leaf extract
10kg of dried lotus leaf is taken, soaked in 40 times (L) of purified water for 20min, heated (80 ℃) for 2 times, filtered after each 1h of extraction, the filtrate is taken as an extracting solution, concentrated extracting solution (normal pressure and 100 ℃) is concentrated, and the extracting solution is dried at 80 ℃ for 36h, thus obtaining 1.2kg of lotus leaf extract.
1.4 identification of the Components of the lotus leaf extract
Taking a lotus leaf extract sample, and detecting the nuciferine content in the lotus leaf extract sample: liquid chromatography (column temperature 30 ℃ C., detection wavelength 270 nm) is adopted, nuciferine is used as a reference substance, methanol is added for dilution, a sample solution of 0.5mg/mL is prepared, acetonitrile-water solution (25.5 mL of triethylamine and 11mL of glacial acetic acid are contained in each 1000mL of water solution; the volume ratio of acetonitrile to water solution=49:51) is used as a mobile phase for elution, linear relation investigation and peak area measurement are adopted, and finally the nuciferine content in the sample is measured to be 1.21%.
(II) in vitro assay of xanthine oxidase inhibition Rate
2.1 preparation of reagent solutions of reagents
2.1.1 preparation of test sample solution sets:
(1) 6.7mg of lotus leaf extract and 13.4mg of ampelopsis grossedentata leaf extract (lotus leaf extract: ampelopsis grossedentata leaf extract=1:2, w/w) are precisely weighed into a 50mL measuring flask, and absolute ethyl alcohol is used for constant volume.
(2) 3.35mg of lotus leaf extract and 13.4mg (lotus leaf extract: ampelopsis grossedentata leaf extract=1:4, w/w) of ampelopsis grossedentata leaf extract are precisely weighed into a 50mL measuring flask, and absolute ethyl alcohol is used for constant volume.
(3) 13.4mg of lotus leaf extract and 6.7mg (lotus leaf extract: ampelopsis grossedentata leaf extract=2:1, w/w) of ampelopsis grossedentata leaf extract are precisely weighed into a 50mL measuring flask, and absolute ethyl alcohol is used for constant volume.
2.1.2 xanthine solution preparation:
15.27mg of xanthine was precisely weighed, 10mL of 0.1mol/L sodium hydroxide solution was added thereto, and the mixture was sufficiently dissolved, and the volume was fixed to 100mL with PBS (pH 7.5) to obtain 1mmol/L xanthine solution.
2.1.3 xanthine oxidase solution preparation:
0.2mg of xanthine oxidase was precisely weighed, dissolved in PBS (pH 7.5) and fixed in a 10mL volumetric flask to obtain 20. Mu.g/mL xanthine oxidase solution.
2.2 inhibition of xanthine oxidase by Ampelopsis grossedentata leaf and lotus leaf extract composition in different proportions
Negative blank: 1.2mL of distilled water was precisely aspirated, and the mixture was thoroughly mixed with 2.8mL of PBS (pH 7.5) and 1mL of xanthine solution to prepare an absorbance measurement.
Sample blank: 0.1mL of the sample solutions (1), (2) and (3) were precisely aspirated, and the resulting mixture was thoroughly mixed with 1.1mL of distilled water, 2.8mL of PBS (pH 7.5) and 1mL of xanthine solution, followed by measurement of absorbance.
Negative group: precisely sucking 2.8mL of PBS (pH 7.5), mixing with 1mL of distilled water and 0.2mL of xanthine oxidase solution uniformly, incubating in a water bath at 37 ℃ for 15min, adding 1mL of xanthine solution, mixing thoroughly, starting reaction at 25 ℃, and measuring absorbance at 1min, 2min, 3min, 4min, 5min, 6min, 7min, 8min, 9min and 10min respectively.
Sample solution group: precisely sucking 0.1mL of sample solutions (1), (2) and (3), mixing with 0.9mL of distilled water, 2.8mL of PBS (pH 7.5) and 0.2mL of xanthine oxidase solution uniformly, incubating in a water bath at 37 ℃ for 15min, adding 1mL of xanthine solution, mixing thoroughly, starting reaction at 25 ℃, and measuring absorbance at 1min, 2min, 3min, 4min, 5min, 6min, 7min, 8min, 9min and 10min respectively.
2.3 experimental results
Detecting xanthine oxidase inhibition activity of a test sample, wherein the xanthine oxidase inhibition rate is calculated according to the formula:
inhibition ratio = [ (Rp-Rs)/Rp ] ×100%
Where Rs, rp represent the reaction rate of the sample (minus the sample blank) and negative (minus the negative blank), respectively (slope is the reaction rate, determined from the slope of the absorbance standard curve at different times).
The results show that the inhibition rate of xanthine oxidase of the tested sample is 51.4%, 55.3% and 37.23% respectively by testing the inhibition rate of xanthine oxidase of the tested sample solutions (1), (2) and (3), namely, when the lotus leaf extract is 1:4 of the ampelopsis grossedentata leaf extract, the inhibition effect of the composition of the lotus leaf extract and the ampelopsis grossedentata leaf extract (1:4) on the xanthine oxidase is strongest, and the inhibition effect of the composition is stronger than that of the single lotus leaf extract and the ampelopsis grossedentata leaf extract (23.15% and 49.55%).
Pharmacological experiment of uric acid reducing action of composition (III) on hyperuricemia mice
3.1 test drug
The lotus leaf extract (HY, 0.18 g/kg), the ampelopsis grossedentata leaf extract (PTY, 0.18 g/kg) and the combination (HY+PTY (1:4), 0.18 g/kg) of the lotus leaf extract and the ampelopsis grossedentata leaf extract (1:4) are taken, dissolved in distilled water and administrated by stomach infusion according to the administration volume of 0.1mL/10 g.
3.2 Positive control drug
Allopurinol tablets were crushed and dissolved in distilled water (administered by gavage at a dose of 10mg/kg/d, and a volume of administration of 0.1mL/10 g).
3.3 grouping and Experimental methods
Hypoxanthine is a precursor substance of uric acid in organism, and injection of hypoxanthine can accumulate uric acid, thereby inducing hyperuricemia; potassium oxazinate can inhibit uricase from decomposing uric acid, so that uric acid decomposition in a body is reduced, and uric acid level is continuously increased, thereby inducing hyperuricemia. The two can be combined to form a model which can obviously induce hyperuricemia and renal function injury.
The SPF-class Kunming male mice were bred adaptively for 4 days, and the experiment was started after confirming that the animal was good in health. Mice were randomly divided into 7 groups according to body weight, namely a Blank (Blank) group, a vehicle control (VE) group, a Model (Model) group, allopurinol (Allopurinol) group, lotus leaf extract (HY) group, hy+pty (1:4) group, ampelopsis grossedentata leaf extract (PTY) group, wherein Allopurinol group was 20, model group was 12, and the rest was 10.
The other groups except the blank control group and the solvent control group are subjected to gastric lavage at the dosage of 500mg/kg for 7 days, the corresponding group of test drugs and positive control drugs are subjected to gastric lavage at intervals of 30min every six days, all mice are fasted in the evening on the sixth day, and after the last administration of the hypoxanthine for 30min on the seventh day, 300mg/kg of potassium oxazinate is injected into the abdominal cavity of the other groups except the blank control group and the solvent control group, and the corresponding group of test drugs and positive control drugs are subjected to gastric lavage at intervals of 20 min. The vehicle control group was given an equal volume of 0.5% sodium carboxymethyl cellulose in water by gavage and 0.5% sodium carboxymethyl cellulose in physiological saline by intraperitoneal injection. The blank control group is not treated and is fed normally.
1h after the intraperitoneal injection of the potassium oxazinate is finished, the orbit is used for taking blood, the blood is placed in a clean centrifuge tube, the blood is kept stand for 2h at room temperature, the blood is obtained after centrifugation for 10min at 3000rpm, and the blood is packaged in a 200 mu L centrifuge tube. And detecting the blood uric acid content in serum by using a uric acid kit.
3.4 experimental results
As can be seen from table 1: after 7 days of hyperuricemia Model modeling, the Model group (Model) showed an extremely significant increase in blood uric acid level (P < 0.001) compared to the vehicle control group; the allopurinol group showed a very significant decrease in blood uric acid number (P < 0.0001) compared to the Model group (Model) 7 days after administration, indicating successful modeling. 7 days after administration, the blood uric acid level of the lotus leaf extract group (0.18 g/kg) was significantly reduced (P < 0.05) compared with the model group; comparing Ampelopsis grossedentata leaf extract (0.18 g/kg) with model, blood uric acid value is extremely significantly reduced (P < 0.01); the HY+PTY (1:4) group (0.18 g/kg) showed a very significant decrease in blood uric acid level (P < 0.001) compared with the model group. Folium Nelumbinis extract group, ampelopsis grossedentata leaf extract group, HY+PTY
The blood uric acid values of the (1:4) groups were 203.01, 171.79 and 140.99. Mu. Mol/L, respectively, and were significantly lower after administration of the combination of lotus leaf extract and ampelopsis grossedentata leaf extract (1:4) than after administration of the lotus leaf extract alone (with statistical difference, P < 0.01) and ampelopsis grossedentata leaf extract alone (with statistical difference, P < 0.05).
TABLE 1 animal experiment groups and statistics of uric acid lowering (UA) actions of different subjects
Note that: comparison with model group P <0.05, P <0.01, P <0.001, P < 0.0001; comparing the model with the HY group, wherein # P is less than 0.01;
compared with PTY group, < P < 0.05.
Pharmacological experiments of uric acid reducing effects of different administration doses of the composition on hyperuricemia mice
4.1 preparation of test drug
The combination of lotus leaf extract and ampelopsis grossedentata leaf extract (1:4) is respectively dissolved in distilled water to prepare low, medium and high dosage (0.09 g/kg, 0.18g/kg respectively) liquid medicine. The administration was performed by gavage in an administration volume of 0.1mL/10 g.
4.2 Positive control drug
Pulverizing allopurinol tablet, dissolving in distilled water (administered by gastric lavage at 10mg/kg/d, administration volume)
0.1mL/10g)。
4.3 grouping and Experimental methods
SPF-class Kunming male mice were kept adaptively for 4 days, and the experiment was started after confirming that the animal was well-conditioned.
Mice were randomly divided into 7 groups of 10 mice each according to body weight. Namely a Blank group, a vehicle control (VE) group, a Model group, an Allopurinol group, and a combination of lotus leaf extract and ampelopsis grossedentata leaf extract (1:4) (HY+PTY (1:4)) in low, medium and high dose groups.
The other groups except the blank control group and the solvent control group are subjected to gastric lavage at the dosage of 500mg/kg for 7 days, the corresponding group of test drugs and positive control drugs are subjected to gastric lavage at intervals of 30min every six days, all mice are fasted in the evening on the sixth day, and after the last administration of the hypoxanthine for 30min on the seventh day, 300mg/kg of potassium oxazinate is injected into the abdominal cavity of the other groups except the blank control group and the solvent control group, and the corresponding group of test drugs and positive control drugs are subjected to gastric lavage at intervals of 20 min. The vehicle control group was given an equal volume of 0.5% sodium carboxymethyl cellulose in water by gavage and 0.5% sodium carboxymethyl cellulose in physiological saline by intraperitoneal injection. The blank group was not subjected to any treatment.
1h after the intraperitoneal injection of the potassium oxazinate is finished, the orbit is used for taking blood, the blood is placed in a clean centrifuge tube, the blood is kept stand for 2h at room temperature, the blood is obtained after centrifugation for 10min at 3000rpm, and the blood is packaged in a 200 mu L centrifuge tube. And detecting the blood uric acid content in serum by using a uric acid kit.
4.4 experimental results
As can be seen from table 2: after 7 days of hyperuricemia Model modeling, the Model (Model) group had a very significant increase in blood uric acid level (P < 0.001) compared to the vehicle control group; after 7 days of administration, allopurinol group showed extremely significant decrease in blood uric acid value (P < 0.0001) compared with Model group. The HE+PTY (1:4) low, medium and high dose (0.09, 0.18, 0.36 g/kg) groups showed a significantly reduced or very significantly reduced blood uric acid level (P <0.05 or P < 0.001) compared to the model group 7 days after dosing.
TABLE 2 animal experiment groups and statistics of Uric Acid (UA) lowering effect of different dosage compositions
Note that: comparison with model group P <0.05, P <0.001, P < 0.0001.
The results show that compared with single extracts (lotus leaf extract and ampelopsis grossedentata leaf extract), the composition of the lotus leaf extract and the ampelopsis grossedentata leaf extract (1:4) has better therapeutic effect on hyperuricemia by establishing a hyperuricemia model of mice caused by combination of hypoxanthine and gastric lavage and intraperitoneal injection of potassium oxazinate, and the uric acid reducing effect is related to the improvement of the inhibition effect on xanthine oxidase by the composition.
In a word, the invention takes the extracts of ampelopsis grossedentata leaves and lotus leaves as main effective components, inhibits the activity of xanthine oxidase in vivo and reduces the generation of blood uric acid. Experiments show that the compatibility of the lotus leaf extract and the ampelopsis grossedentata leaf extract not only can strengthen the nutrition efficacy, but also can achieve the aim of remarkably improving the functionality (such as more obvious uric acid reducing effect). Meanwhile, the ampelopsis grossedentata leaves and the lotus leaves are both derived from plants, so that the ampelopsis grossedentata has rich resources and high safety, and has wide development prospect.
Claims (2)
1. A uric acid lowering active composition of matter characterized by: the composition comprises Ampelopsis grossedentata leaf extract and folium Nelumbinis extract;
the Ampelopsis grossedentata leaf extract is prepared by extracting Ampelopsis grossedentata leaves with water, concentrating and drying;
the lotus leaf extract is prepared by extracting lotus leaves with water, concentrating and drying;
the mass ratio of the ampelopsis grossedentata leaf extract to the lotus leaf extract in the composition is 4:1.
2. Use of a uric acid lowering active substance composition as defined in claim 1 for the manufacture of a medicament for the treatment of hyperuricemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211071108.0A CN115444893B (en) | 2022-09-02 | 2022-09-02 | Uric acid reducing active substance composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211071108.0A CN115444893B (en) | 2022-09-02 | 2022-09-02 | Uric acid reducing active substance composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115444893A CN115444893A (en) | 2022-12-09 |
| CN115444893B true CN115444893B (en) | 2023-07-07 |
Family
ID=84300756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211071108.0A Active CN115444893B (en) | 2022-09-02 | 2022-09-02 | Uric acid reducing active substance composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115444893B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116210900B (en) * | 2022-12-29 | 2024-01-30 | 抱朴生命科技(广州)有限公司 | Plant polyphenol sustained-release composition for regulating xanthine oxidase activity and accurate nutrient and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016071505A1 (en) * | 2014-11-07 | 2016-05-12 | Danmarks Tekniske Universitet | Microbial production of the flavonoids garbanzol, resokaempferol and fisetin |
| CN106031725A (en) * | 2016-05-18 | 2016-10-19 | 广东奇方药业有限公司 | Drug application of nuciferine and analogue thereof |
| JP2018043985A (en) * | 2016-09-07 | 2018-03-22 | 株式会社ファンケル | Ampelopsin-containing composition for reducing urine acid level in blood |
| CN108686123A (en) * | 2018-07-16 | 2018-10-23 | 何利均 | A kind of Chinese medicine for treating gout |
| CN110420293A (en) * | 2019-07-31 | 2019-11-08 | 天津尖峰弗兰德医药科技发展有限公司 | The plant composition and plant composition solid particle for treating hyperuricemia and gout |
| CN111973704A (en) * | 2020-08-11 | 2020-11-24 | 中山市中智药业集团有限公司 | Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof |
| CN113115942A (en) * | 2021-06-08 | 2021-07-16 | 安徽壹心德生物科技有限公司 | Blood fat reducing dietary formula and processing technology thereof |
| JP2021109869A (en) * | 2020-01-09 | 2021-08-02 | オリザ油化株式会社 | AGE production inhibitor |
| CN114470072A (en) * | 2022-01-27 | 2022-05-13 | 湖北省农业科学院中药材研究所 | Ampelopsis grossedentata extract, preparation method thereof and application thereof in preparation of diuretic drugs |
-
2022
- 2022-09-02 CN CN202211071108.0A patent/CN115444893B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016071505A1 (en) * | 2014-11-07 | 2016-05-12 | Danmarks Tekniske Universitet | Microbial production of the flavonoids garbanzol, resokaempferol and fisetin |
| CN106031725A (en) * | 2016-05-18 | 2016-10-19 | 广东奇方药业有限公司 | Drug application of nuciferine and analogue thereof |
| JP2018043985A (en) * | 2016-09-07 | 2018-03-22 | 株式会社ファンケル | Ampelopsin-containing composition for reducing urine acid level in blood |
| CN108686123A (en) * | 2018-07-16 | 2018-10-23 | 何利均 | A kind of Chinese medicine for treating gout |
| CN110420293A (en) * | 2019-07-31 | 2019-11-08 | 天津尖峰弗兰德医药科技发展有限公司 | The plant composition and plant composition solid particle for treating hyperuricemia and gout |
| JP2021109869A (en) * | 2020-01-09 | 2021-08-02 | オリザ油化株式会社 | AGE production inhibitor |
| CN111973704A (en) * | 2020-08-11 | 2020-11-24 | 中山市中智药业集团有限公司 | Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof |
| CN113115942A (en) * | 2021-06-08 | 2021-07-16 | 安徽壹心德生物科技有限公司 | Blood fat reducing dietary formula and processing technology thereof |
| CN114470072A (en) * | 2022-01-27 | 2022-05-13 | 湖北省农业科学院中药材研究所 | Ampelopsis grossedentata extract, preparation method thereof and application thereof in preparation of diuretic drugs |
Non-Patent Citations (6)
| Title |
|---|
| 中药活性成分降尿酸作用机制研究进展;周洁，等;中国药理学通报;第34卷(第01期);第19-22页 * |
| 复方鹿衔草总黄酮纯化工艺优选;陈吼，等;现代中医药;第33卷(第02期);第89-91页 * |
| 痛风停药效学实验研究;张艺芳，等;内蒙古中医药;第33卷(第25期);第79-80页 * |
| 药食两用中草药在防治高尿酸血症上的研究进展;郭花斌，等;世界最新医学信息文摘;第18卷(第86期);第50-51、53页 * |
| 藤茶和荷叶提取物对高脂血症大鼠降血脂作用的实验研究;杨新跃，等;中国比较医学杂志;第15卷(第05期);第281-284页 * |
| 藤茶提取物中二氢杨梅素对大鼠急性痛风性关节炎模型的影响;卢忠英，等;中国现代应用药学;第32卷(第04期);第396-399页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115444893A (en) | 2022-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1468859A (en) | Longbract cattail general flavone extractive and its prepn and use | |
| CN1742763A (en) | Use of Wucenglong extract in preparing health-care product and medicines | |
| CN109010414B (en) | Use of extract of Pithecellobium clypearia for preventing and/or treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| CN115444893B (en) | Uric acid reducing active substance composition and application thereof | |
| CN102068494B (en) | Health-care capsules with treatment effect on chemical liver injury and preparation method thereof | |
| JP2001508777A (en) | Pine needle extract and its use | |
| CN111166820B (en) | Traditional Chinese medicine composition containing fingered citron, preparation and application | |
| CN102014944B (en) | Pharmaceutical composition using herbal extract for prevention and treatment of obesity and metabolic disorders | |
| CN102836281A (en) | Application of lycium ruthenicum murray total flavone extract | |
| CN101120977B (en) | Medicine for treating tumor | |
| CN102836282B (en) | Application of folium lycii total flavone extract | |
| CN106822338B (en) | Compound composition for reducing blood sugar and blood fat and preventing and/or treating diabetes and complications thereof and application thereof | |
| CN1788758A (en) | Use of traditional Chinese medicine garden burnet and its extract in preparing drug for raising red cell and blood hemoglobin | |
| EP2124980A1 (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| CN100434085C (en) | Process for removing toxic component from oleum fructus bruceae | |
| CN106511394B (en) | Application of aspongopus fatty oil extract | |
| CN105535007A (en) | Use of icariin and derivatives thereof for preventing and treating mental disorders | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN103054848B (en) | Pharmaceutical composition for preventing or treating cardiovascnlar and cerebrovascular diseases | |
| CN105640792B (en) | Dihydromyricetin is in beauty except the application in spot product | |
| CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN111568935B (en) | Application of Siberian cocklebur fruit extract in preparation of antitumor drugs | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease | |
| Ravash et al. | The effect of hydroalcoholic extracts from Taraxacum officinale on blood indicators of kidney and liver functions in male rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |